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The authors examined the associations of toenail selenium levels with blood concentrations of fibrinogen, high-
sensitivity C-reactive protein (hs-CRP), and interleukin-6 (IL-6) in an 18-year follow-up study comprising 4,032
Americans aged 20–32 years at baseline (1987) from the Coronary Artery Risk Development in Young Adults
(CARDIA) Trace Element Study. Toenail samples were collected in 1987, and selenium concentrations were
measured by means of instrumental neutron-activation analysis. Fibrinogen level was analyzed in 1990, 1992,
and 2005; hs-CRP was assessed in 1992, 2000, and 2005; and IL-6 was measured in 2005. After adjustment for
potential confounders, no statistically significant associations between toenail selenium levels and any of the
3 inflammatory biomarkers were documented. Comparing the highest quintile of toenail selenium level with the
lowest, odds ratios for elevated levels of fibrinogen (>460 mg/mL), hs-CRP (>3 lg/mL), and IL-6 (>3.395 pg/mL,
80th percentile) were 1.03 (95% confidence interval (CI): 0.77, 1.38; P for trend ¼ 0.76), 1.02 (95% CI: 0.83, 1.27;
P for trend¼ 0.92), and 0.98 (95% CI: 0.71, 1.36; P for trend¼ 0.82), respectively. Gender, race/ethnicity, smoking
status, and selenium supplementation did not appreciably modify these results. This study found no associations
between toenail selenium and inflammation as measured by fibrinogen, hs-CRP, and IL-6.
C-reactive protein; fibrinogen; inflammation; interleukin-6; nails; selenium
Abbreviations: CARDIA, Coronary Artery Risk Development in Young Adults; hs-CRP, high-sensitivity C-reactive protein; IL-6,
interleukin-6; NHANES III, Third National Health and Nutrition Examination Survey; WHAS I, Women’s Health and Aging Study I.
The recognition of selenium’s role in preventing oxida-
tive damage has ignited research into the association
between selenium and various chronic inflammatory con-
ditions. Serum selenium level was observed to be inversely
associated with rheumatoid factor-negative arthritis in
a large case-control study nested in a Finnish cohort (1).
Selenium was also found to be protective against other
possible inflammation-related diseases, including asthma
(2) and pancreatitis (3), in the United Kingdom. In addi-
tion, low selenium levels have been found to be associated
with some autoimmune conditions, such as autoimmune
hepatitis and type 1 diabetes (4, 5). Thus, it has been hy-
pothesized that selenium, incorporated into selenoproteins
as an antioxidant, can lower levels of inflammatory
biomarkers (6).
However, data directly relating selenium to inflammatory
markers or cardiovascular disease risk factors are sparse.
Investigators from the Women’s Health and Aging Study I
(WHAS I) reported an inverse correlation between serum
selenium levels and interleukin-6 (IL-6) levels in disabled
elderly women (7). A study using data from the Third
National Health and Nutrition Examination Survey
(NHANES III) also found an inverse association between
blood selenium and C-reactive protein (8). In addition, an-
other cross-sectional study found that intake of selenium
was associated with lower levels of high-sensitivity
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C-reactive protein (hs-CRP) in women (9). In contrast, in
a randomized trial, Stranges et al. (10) found that selenium
supplementation of 200 lg/day increased the risk of type 2
diabetes mellitus, which may be linked to inflammatory
markers (11). Further, in a recent large-scale, randomized,
placebo-controlled trial, Lippman et al. (12) found no asso-
ciation between selenium supplementation of 200 lg /day
and cardiovascular endpoints. Notably, prospective epide-
miologic data on the long-term association between sele-
nium and biomarkers of inflammation are lacking.
Toenail selenium level is recognized as a reliable bio-
marker reflecting relatively long-term selenium status
(13, 14). As inflammatory biomarkers, hs-CRP and IL-6
have been widely used, not only in experimental studies
but also in epidemiologic studies, for predicting atheroscle-
rosis and cardiovascular disease (15, 16). Fibrinogen is an
established clotting factor and is also considered a marker
for chronic low-grade inflammation (17, 18). Our purpose in
this study was to examine the long-term associations be-
tween toenail selenium levels and levels of 3 available in-
flammatory biomarkers—fibrinogen, hs-CRP, and IL-6—in
the Coronary Artery Risk Development in Young Adults
(CARDIA) Trace Element Study.
MATERIALS AND METHODS
Study population
The CARDIA cohort was established in 1985, when
5,115 American young adults aged 18–30 years partici-
pated in a study of psychological and lifestyle factors that
might affect the evolution of coronary artery disease risk.
Details of the study design have been published elsewhere
(19). Briefly, the cohort was roughly balanced by age
(<25 years, 25 years), gender, education (high school,
>high school), and race/ethnicity (African-American,
Caucasian) and was recruited from 4 US metropolitan
areas (Birmingham, Alabama; Chicago, Illinois;
Minneapolis, Minnesota; and Oakland, California). Six
follow-up examinations have been conducted, in 1987,
1990, 1992, 1995, 2000, and 2005. Approximately 70%
of participants in the original cohort returned for the sixth
visit in 2005, and follow-up rates averaged 94% in each
examination cycle. In the present study, 1987 was consid-
ered the baseline date, since toenail specimens were col-
lected in that year. A total of 4,624 participants attended
the 1987 examination, of which 4,362 (94.3%) provided
toenail clippings. In this analysis, we excluded partici-
pants who had missing data on toenail weight (n ¼ 75)
and those who had an extremely high level of toenail se-
lenium (2 lg/g; n ¼ 28), since, based on our laboratory
experience, this high concentration is probably due to ex-
ogenous contamination. We also excluded participants
who had no data on any of the 3 biomarkers of inflamma-
tion (n ¼ 222) and those who had arthritis (n ¼ 5). After
these baseline exclusions, 4,032 participants were in-
cluded in this analysis.
All participants gave informed consent. The study design,
data collection, and analyses were approved by the institu-
tional review boards of the participating institutions.
Analysis of exposure
Toenail clippings were collected from all 10 toes by the
participants themselves with a stainless steel clipper during
the clinical examination. All toenail clippings were pro-
cessed with a washing procedure in a sonicator with deion-
ized water. Selenium levels were analyzed by means of
instrumental neutron-activation analysis at the University
of Missouri Research Reactor (20). Toenail specimens were
treated in random order by the laboratory personnel, who
were blinded to other clinical measures. In the present study,
the average coefficient of variation in duplicate subsamples
for the toenail selenium measurement was 2.45%.
Animal studies suggest that toenail selenium level is best
suited for measuring skeletal muscle and heart selenium
status. The correlations between toenail selenium and skel-
etal muscle and heart selenium content were 0.75 and 0.76,
respectively (21). In addition, toenail selenium concentra-
tion from a single sample represents exposure over a period
of 9–12 months (22, 23). The Spearman correlation coeffi-
cient for the reproducibility of toenail selenium over a period
of 6 years has been shown to be 0.48 (24). In a pilot study we
conducted in 2007 among 64 randomly selected CARDIA
participants from Chicago field center, the Spearman corre-
lation coefficient for the correlation between toenail sele-
nium concentrations in toenail clippings collected 20 years
apart and measured by the same laboratory with the same
protocol was 0.56.
Measurements of inflammatory biomarkers
Fibrinogen was measured 3 times, in 1990, 1992, and
2005. In 1990, fibrinogen was assessed via the Clauss
method using reagents from the Dade Behring division
of Baxter Healthcare Corporation (Dade Behring Inc.,
Deerfield, Illinois) (25). In 1992 and 2005, fibrinogen anti-
gen was measured using the BN-II nephelometer (N Anti-
serum to Human Fibrinogen; Dade Behring Inc.) and
calibrated with standard normal plasma (SNP reagent; Dade
Behring Inc.), which was also selected for consistency with
the previously utilized Claus method (18, 26).
Serum hs-CRP was measured in blood samples collected
in 1992, 2000, and 2005 using a new enzyme-linked immu-
nosorbent assay method improved with a nephelometry-
based high-throughput assay that offers greater sensitivity
and reproducibility (27). IL-6 was measured in 2005 only
with a high-sensitivity enzyme-linked immunosorbent assay
(R&D Systems, Minneapolis, Minnesota) (28).
Assessment of covariates
Data on demographic variables were collected via ques-
tionnaire. Smoking status was determined by self-report at
each examination and was classified into 3 groups: current,
former, and never smokers. Alcohol consumption was as-
sessed with a self-administered questionnaire and as part of
a dietary interview at each examination. Weight and height
were directly measured while the participant stood in light
clothes without shoes. Body mass index (weight (kg)/height
(m)2) was classified into 5 groups: <21, 21–22.9, 23–24.9,
25–29.9, and 30 (29). At each examination, blood pressure
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was measured on the right arm with a random-zero sphyg-
momanometer after the participant had rested for 5 minutes.
Systolic and diastolic blood pressures were recorded as
phase I and phase V Korotkoff sounds. Physical activity
was assessed using the interview-based, validated CARDIA
Physical Activity History Questionnaire (30). A score of
100 exercise units is approximately equivalent to participa-
tion in vigorous activity for 2–3 hours per week during 6
months of the year. Diet was assessed by means of the
validated CARDIA Diet History Questionnaire at the
1985, 1992, and 2005 examinations. We also took data on
supplement use into account to assess intakes of related
micronutrients and vitamins.
Statistical analysis
Participants were divided into quintiles according to their
toenail selenium levels. Group comparisons of characteristics
at baseline were performed using analysis of variance, the
Kruskal-Wallis test, or the chi-squared test as appropriate.
Binary variables for all 3 inflammatory markers were
created. The cutoff values for fibrinogen (>460 mg/L) and
hs-CRP (>3 lg/L) were determined on the basis of the liter-
ature (31, 32). The generalized estimating equations method
with logit linkage was used to calculate multivariable-adjusted
prospective odds ratios and 95% confidence intervals for
elevated levels of fibrinogen or hs-CRP. Since there is no
commonly used cutoff value for IL-6, we defined this binary
variable by using its 80th percentile. A logistic regression
model was used to estimate odds ratios and 95% confidence
intervals for elevated IL-6 level. We considered 3 sequential
models in the analysis of each inflammatory marker: Model 1
adjusted for age, gender, race/ethnicity, and study center;
model 2 additionally adjusted for education, smoking status,
alcohol consumption, physical activity, body mass index,
and toenail mass; and model 3 additionally adjusted for
baseline dietary intake of vitamin C, folic acid, zinc, vitamin
E, and b-carotene. We created an ordinal variable for selenium
using the median level of toenail selenium in each quintile for
the trend test.
We also considered continuous outcomes for the 3
markers. Box-Cox transformation was used to improve the
normality of the distributions of fibrinogen, hs-CRP, and IL-
6. Because fibrinogen and hs-CRP were measured multiple
times, generalized estimating equations were used to exam-
ine the associations between selenium levels and these 2
inflammatory biomarkers; since IL-6 was measured once,
the general linear model was used. The sequential modeling
strategy described above was used in all models. In addition,
we used a nonparametric spline in sensitivity analysis to
detect whether there was any ‘‘threshold’’ association.
All analyses were performed using SAS, version 9.1.3
(SAS Institute Inc., Cary, North Carolina). P  0.05 was
considered statistically significant.
RESULTS
Baseline characteristics of the 4,032 study participants
are shown in Table 1. The median toenail selenium levels
across quintiles were 0.69, 0.78, 0.84, 0.91, and 1.04 lg/g.
As compared with participants in the lowest quintile of
selenium level, those in the highest quintile were slightly
older and were more likely to be female, Caucasian, and
non-current smokers. They also had a higher educational
level and higher intakes of vitamin C, folic acid, vitamin
E, b-carotene, and zinc but had lower alcohol consumption
and lower body mass index. Toenail selenium levels varied
geographically by study center. Selenium levels were rela-
tively lower in males, African Americans, current smokers,
and participants with high alcohol consumption (Table 1).
In the logistic regression analysis for binary outcomes of
elevated inflammatory marker levels, the multivariable-
adjusted odds ratios were 1.03 (95% confidence interval:
0.77, 1.38; P for trend ¼ 0.76) for fibrinogen, 1.02 (95%
confidence interval: 0.83, 1.27; P for trend ¼ 0.92) for hs-
CRP, and 0.98 (95% confidence interval: 0.71, 1.36; P for
trend ¼ 0.82) for IL-6, comparing the highest quintile of
selenium level with the lowest (Table 2). Gender, race/
ethnicity, smoking status, and supplement use did not ap-
preciably modify the observed null associations (Figure 1).
We also considered the 3 markers as continuous outcomes
and calculated multivariable-adjusted regression coeffi-
cients and their 95% confidence intervals. Consistently, no
statistically significant associations were found (data not
shown).
We conducted sensitivity analyses to test the robustness
of our findings (data not shown). First, when we excluded
participants with self-reported asthma (n ¼ 49), allergic
disease (n ¼ 5), and acute pancreatitis (n ¼ 1) at baseline,
the results remained the same. Second, when we further
excluded those who reported thyroid problems (hyperthy-
roidism, hypothyroidism, goiter, or other thyroid problems;
n¼ 71), the results were not appreciably changed. Third, the
results were similar when we additionally adjusted for in-
take of long-chain omega-3 polyunsaturated fatty acids in
the model; previous studies had suggested a beneficial effect
of these fatty acids on inflammation (33) and a possible in-
teraction between these fatty acids and selenium (34). In
addition, there was no significant interaction between intake
of omega-3 fatty acids or fish and toenail selenium in re-
lation to any of the 3 inflammatory biomarkers. Finally,
because we had multiple measurements of fibrinogen and
hs-CRP, we examined the associations by separately relating
toenail selenium levels to fibrinogen/hs-CRP measured
at different time points; the null associations remained
consistent, and no secular trend was found.
DISCUSSION
In this large prospective cohort study, we found no sig-
nificant long-term associations between toenail selenium
levels and blood concentrations of fibrinogen, hs-CRP, and
IL-6 among healthy American young adults. Gender, race/
ethnicity, smoking status, and selenium supplementation did
not materially modify these results.
Our findings are unlikely to be explained by low statisti-
cal power, because 4,032 participants and the use of contin-
uous outcomes guaranteed approximately 99% power to
detect a 0.05-unit change in each inflammatory biomarker
when comparing the 2 extreme quintiles of selenium level
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Table 1. Baseline Characteristics of American Young Adults According to Quintile of Toenail Selenium Level, CARDIA Trace Element Study, 1987–2005
Characteristic
Quintile of Toenail Selenium Level
Total P Valuea
1 2 3 4 5
No. of participants 808 806 814 803 801 4,032
Selenium level, lg/g
Median 0.69 0.78 0.84 0.91 1.04 0.84
Range 0.479–0.737 0.738–0.807 0.808–0.877 0.878–0.960 0.961–1.978 0.479–1.978
Mean age, years (SD) 26.8 (3.6) 26.8 (3.6) 27.0 (3.6) 27.2 (3.7) 27.2 (3.6) 27.0 (3.6) 0.08
Female gender, % 40.1 49.4 53.7 62.5 69.5 55.0 <0.01
Black race/ethnicity, % 60.9 50.1 45.6 46.3 37.0 48.0 <0.01
Mean education, years (SD) 13.6 (2.2) 14.1 (2.4) 14.3 (2.3) 14.2 (2.4) 14.5 (2.4) 14.2 (2.3) <0.01
Current smoker, % 45.1 30.7 27.6 22.7 17.7 28.8 <0.01
Selenium supplementation, % 27.0 29.0 31.8 29.0 33.6 30.1 0.03
Alcohol intake, mL/day
Median 12.2 6.8 6.1 6.1 5.1 6.4 <0.01
IQRb 3.0–27.1 0–17.6 0–15.6 0–16.2 0–14.2 0–17.6
Physical activity scorec
Median 332.0 306.5 323.5 307.0 317.0 318.0 0.32
IQR 171.0–580.0 170.0–528.0 174.0–534.0 158.0–516.0 167.0–507.0 168.0–531.0
Dietary intake, mg/1,000 kcal/day
Vitamin C
Median 55.1 63.1 68.2 69.8 75.0 66.4 <0.01
IQR 37.7–87.6 40.7–98.6 45.6–108.5 45.4–110.1 48.7–121.5 42.7–104.1
Folic acid
Median 110.7 119.3 124.2 129.1 128.4 122.5 <0.01
IQR 86.5–153.1 89.1–178.8 95.7–183.3 92.8–199.5 97.4–221.4 91.9–185.8
Vitamin E
Median 3.6 3.8 3.7 4.1 4.2 3.9 <0.01
IQR 2.8–4.6 3.0–5.3 3.0–5.4 3.1–6.1 3.2–6.4 3.0–5.5
b-carotene
Median 963.1 1,020.9 1,094.7 1,148.2 1,209.1 1,070.6 <0.01
IQR 619.7–1,496.5 654.3–1,714.7 727.8–1,816.9 710.6–2,123.5 733.5–2,137.8 687.9–1,805.8
Zinc (mean) (SD) 6.8 (3.5) 7.1 (4.0) 7.0 (3.3) 7.6 (8.2) 7.7 (7.1) 7.2 (5.6) <0.01
Mean body mass indexd (SD) 25.4 (5.2) 25.3 (5.1) 25.1 (5.2) 25.4 (5.8) 24.6 (5.1) 25.2 (5.3) 0.02
Mean toenail mass, mg (SD) 23.7 (6.8) 23.5 (6.7) 23.8 (6.6) 23.7 (6.3) 24.0 (6.3) 23.7 (6.5) 0.51
Abbreviations: CARDIA, Coronary Artery Risk Development in Young Adults; IQR, interquartile range; SD, standard deviation.
a P for any difference across the quintiles of toenail selenium level, obtained using analysis of variance, the Kruskal-Wallis test, or the chi-squared test as appropriate.
b 25th–75th percentiles.
c Physical activity was assessed using the CARDIA Physical Activity History Questionnaire (30).



































with a standard deviation of 0.2 and a 2-tailed, Bonferroni
correction alpha level of 0.005. Our results are also unlikely
to have been substantially biased by confounders, since we
used biomarkers for both exposure and outcomes and se-
quentially adjusted for a number of potential confounders,
including major lifestyle, dietary, and nondietary factors.
However, the possibility of residual confounding and con-
founding from unmeasured factors cannot be excluded be-
cause of the nature of observational studies. In addition,
selenium level was measured in toenails in this study.
Toenail selenium is recognized as the best indicator of rel-
atively long-term selenium exposure compared with other
biomarkers such as blood selenium. The range of toenail
selenium levels in this study was 0.48–1.98 lg/g, which
provided wide variation and enabled us to examine any
possible association between selenium and inflammatory
biomarkers. Moreover, one may observe a null association
if the exposure variation falls within a flat portion of a non-
linear relation (i.e., threshold). However, the likelihood of
this is low, since there was no ‘‘threshold’’ phenomenon
detected in a nonparametric spline analysis. Furthermore,
the consistent results across all 3 available inflammatory
biomarkers and from sensitivity analyses strengthened our
study and increased the robustness of our findings.
In addition to the inherent limitations of observational
studies, this study had a few other limitations. First, toenail
selenium was measured only at baseline. Thus, we were
unable to study the effects of changes in selenium status
on inflammatory biomarkers over the 18-year follow-up pe-
riod. For example, if participants with low selenium levels at
baseline increased their intakes of selenium later on, any
possible association would be attenuated. However, results
were consistent when we further adjusted for, or stratified
data according to, selenium supplement use. Further, be-
cause of budget and other practical constraints, it is not un-
common for investigators in longitudinal epidemiologic
studies to utilize 1 measurement of exposure at baseline
with an assumption that this single measurement represents
long-term exposure status (35, 36). Second, although good
long-term reproducibility of toenail measurements was sug-
gested by 1 published study (24) and by our pilot study, it is
possible that random measurement error could prevent the
detection of any weak or moderate long-term association.
Third, a narrow safety range of selenium intake has been
Table 2. Multivariable-Adjusted Odds Ratios for Elevated Levels of Inflammation Biomarkers by Quintile of Toenail Selenium Level, CARDIA
Trace Element Study, 1987–2005a
Inflammation Biomarker
Quintile of Toenail Selenium Level
P for
Trendb1
2 3 4 5
(Referent) OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Fibrinogen (>460 mg/dL)
No. of participants 798 799 809 797 798
No. of events 170 163 172 168 168
Model 1c 1.00 1.16 0.90, 1.50 1.01 0.78, 1.31 1.02 0.77, 1.34 1.03 0.78, 1.36 0.82
Model 2d 1.00 1.29 0.99, 1.67 1.10 0.84, 1.43 1.13 0.85, 1.51 1.02 0.76, 1.37 0.70
Model 3e 1.00 1.28 0.99, 1.67 1.12 0.85, 1.46 1.15 0.86, 1.53 1.03 0.77, 1.38 0.76
High-sensitivity C-reactive protein (>3 lg/mL)
No. of participants 770 776 780 762 781
No. of events 339 318 332 318 309
Model 1 1.00 1.11 0.92, 1.34 1.00 0.82, 1.22 1.06 0.87, 1.30 1.14 0.93, 1.40 0.30
Model 2 1.00 1.13 0.93, 1.38 0.97 0.79, 1.19 1.06 0.86, 1.30 1.03 0.83, 1.28 0.99
Model 3 1.00 1.13 0.93, 1.37 0.97 0.79, 1.18 1.04 0.85, 1.28 1.02 0.83, 1.27 0.92
Interleukin-6 (>3.395 pg/mL, 80th percentile)
No. of participants 572 628 613 628 638
No. of events 134 118 137 104 123
Model 1 1.00 0.83 0.62, 1.11 1.10 0.82, 1.46 0.72 0.53, 0.99 0.88 0.65, 1.21 0.34
Model 2 1.00 0.83 0.62, 1.12 1.14 0.85, 1.54 0.75 0.54, 1.04 0.97 0.70, 1.35 0.79
Model 3 1.00 0.84 0.62, 1.14 1.15 0.85, 1.55 0.77 0.55, 1.06 0.98 0.71, 1.36 0.82
Abbreviations: CARDIA, Coronary Artery Risk Development in Young Adults; CI, confidence interval; OR, odds ratio.
a Generalized estimating equations with binary outcomes were used for repeated measurements of fibrinogen and high-sensitivity C-reactive
protein; a logistic regression model was used for interleukin-6.
b An ordinal selenium variable using the median toenail selenium level in each quintile was created for the trend tests.
c Adjusted for age, gender (male, female), race/ethnicity (African-American, Caucasian), and study center.
d Additionally adjusted for education (12, 13–15, or 16 years), smoking status (never smoker, former smoker, or current smoker), alcohol
consumption (0, 0.1–11.9, 12.0–23.9, or 24 mL/day), physical activity score (quintiles), body mass index (weight (kg)/height (m)2; <21, 21–22.9,
23–24.9, 25–29.9, 30), and toenail mass (mg; quintiles).
e Additionally adjusted for intakes (quintiles) of vitamin C, folic acid, zinc, vitamin E, and b-carotene at baseline.
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recently suggested (37), while selenium intake is relatively
high in the US population (38–40). The possibility cannot be
excluded that our null association findings were due to the
relatively high selenium intake of this particular population.
Selenium intake above a certain level may not increase se-
lenoprotein antioxidant properties (37). Therefore, if the
selenium level in the reference group was high enough to
provide full antioxidant benefits, further selenium intake
might not offer any additional benefits. Finally, because
our findings were based on a cohort of American young
adults from 4 urban areas, their generalizability may be
limited.
In addition, our results were not consistent with findings
from the WHAS I (7) and NHANES III (8), which found an
inverse association between selenium and IL-6 or C-reactive
protein. Notably, these 2 studies measured blood selenium
levels, which may reflect a different exposure time frame
than toenail selenium. In addition, the WHAS I and
NHANES III were cross-sectional studies. The fact that
we found no long-term association does not discount the
possibility of a short-term relation between selenium and
inflammatory biomarkers. Moreover, the inconsistent results
may be partially due to the different study populations.
Experimental studies suggest that oxidative stress may
promote inflammation (41, 42). Acting as an antioxidant,
selenium has been shown to benefit patients with inflamma-
tory diseases (1–4, 43, 44). However, concern has been
raised because recent studies have suggested a narrow safety
range of selenium intake. A recent large-scale, randomized,
placebo-controlled trial found that selenium supplementa-
tion did not reduce risk of cardiovascular disease (12). Our
study provides further evidence that a high selenium level
may not be beneficial for the prevention of cardiovascular
disease, even over a long time period. Nevertheless, further
studies are warranted to confirm these findings in different
populations with different selenium status and to better un-
derstand the potential mechanism of action between
selenium and inflammatory biomarkers.
In conclusion, this prospective cohort study did not dem-
onstrate any associations between toenail selenium levels
and inflammation as measured by fibrinogen, hs-CRP, and
IL-6 among apparently healthy American young adults. The
null associations remained consistent across subgroups of
gender, race/ethnicity, selenium supplement use, and
smoking status.
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Figure 1. Relations between toenail selenium concentration (lg/g) and levels of inflammatory biomarkers (fibrinogen (mg/dL), high-sensitivity
C-reactive protein (hs-CRP; lg/mL), and interleukin-6 (IL-6; pg/mL)), determined by comparing the highest quintile of toenail selenium level with the
lowest, by gender, race/ethnicity, smoking status, and use of selenium supplements, CARDIA Trace Element Study, 1987–2005. Results were
adjusted for the covariates listed for model 3 in Table 2. Bars, 95% confidence interval (CI).
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